tirzepatide trials In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Weight-loss jab Mounjaro trial begins

There is not a single published randomized controlled trial of subcutaneous GHK-Cu in humans for any aesthetic, hair, or longevity endpoint

Decreasing the conductance of voltage-dependent potassium channels, Kv1.3, is the possible ionic mechanism of GLP-1-induced enhancement of MC excitability (Thiebaud et al., 2016)

Collagen synthesis is protein-dependent at a substrate level even when GHK-Cu provides the signaling stimulus

These multifaceted metabolic effects position dual GLP-1/GIP receptor agonists as superior therapeutic candidates for MASLD, especially in patients with coexisting obesity and T2DM, where dysregulated glucose and lipid metabolism drive the progression of the disease